Spain approves Wegovy, the first oral treatment for obesity
The pharmaceutical company Novo Nordisk will market Wegovy in Spain, the first prescription oral treatment for overweight or obese patients
The pharmaceutical company Novo Nordisk will be responsible for marketing the oral presentation of Wegovy (semaglutide 25 mg) in Spain, the first treatment of its kind for weight loss and obesity management.
Wegovy will be marketed in Spain without public funding, at a cost of €236.20 for a 30-tablet dose.
“The medication, administered as daily tablets taken in the morning, works as a GLP-1 receptor agonist that increases the feeling of satiety in the body.”
It was approved for use in adults with a “Body Mass Index (BMI) of 30 or higher, or from a BMI of 27 in the presence of weight-related comorbidities, always as a complement to a low-calorie diet and physical activity.”
The developing company presented data from the Oasis 4 clinical trial, which showed an average body weight reduction of 16.6 % at the end of 64 weeks of follow-up, “achieving a loss of more than 20 % in one-third of the patients evaluated in the study.”
M.Pino
Source: 2001online
(Reference image source: Jorge Campos on Unsplash)
Follow our news on Google! For current, interesting, and accurate information, click here to see all the content on Bitfinance.news. You can also find us on X/Twitter and Instagram
